At PCR, Interventional Cardiology Looks East, Not West
Executive Summary
For many years, the Paris Course on Revascularization, Europe's largest showcase of devices and technology used in interventional cardiology, more often looked like a mini-TCT, the US-based meeting serving interventional medicine as well. But in the last couple of years, it's been hard to miss a somewhat diminished role for US physicians. While fewer US physicians have made the trip to Paris, interventionalists from China and India have been coming to PCR in greater numbers.
You may also be interested in...
Cardionovum: As DEBs Heat Up, Who Needs The US Market?
German serial entrepreneur Michael Orlowski achieved a successful exit in his first cardiovascular device company, EuroCor, by selling not to a US-based giant, but to an Indian conglomerate, Opto Circuits. His new company, Cardionovum, has developed a next-generation drug-eluting balloon whose novelty rests on a different approach to the coating technology designed to produce better drug-elution. With CE mark in hand, Cardionovum is preparing to launch its products in Europe. The US is a logical next target, but the high cost of clinical trials and the ever-lengthening regulatory approvals process has made the US an even more difficult market to penetrate, forcing companies like Cardionovum to contemplate strategies that bypass or put off a US launch.
Reverse Innovation: Is The US Losing Its Edge In Innovation?
Is US-style innovation in the medical device industry heading towards extinction? Gone are the days when companies believed they could build robust businesses by serving largely, if not exclusively, the US market. Today, emerging markets have become growth markets. But those markets, and even a post-health care reform US, challenge an innovation model that used to reward even incremental technology enhancements with premium pricing, by a price-insensitive customer.
Kanghui: A New Strategic Opens The Door To Orthopedics In China
China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.